Acriflavine inhibits acquired drug resistance by blocking the epithelial-to-mesenchymal transition and the unfolded protein response

Translational Oncology

Volumn 10, Issue 1, 2017, Pages 59-69

  Dekervel, Jeroen ^a   Bulle, Ashenafi ^a,b   Windmolders, Petra ^a   Lambrechts, Diether ^c,d   Van Cutsem, Eric ^a,b,e   Verslype, Chris ^a,b,e   van Pelt, Jos ^a,b,e  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c KU Leuven and University Hospitals Leuven and Leuven Cancer Institute   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e Katholieke Universiteit   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIFLAVINE; ACTIVATING TRANSCRIPTION FACTOR 4; COBALT CHLORIDE; COMPLEMENTARY DNA; INITIATION FACTOR 2ALPHA; SORAFENIB; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL INVASION ASSAY; CONTROLLED STUDY; DNA MICROARRAY; DNA TRANSCRIPTION; DOWN REGULATION; DRUG SENSITIVITY; DRUG SENSITIZATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETIC MARKER; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; HYPOXIA; PANCREATIC CANCER CELL LINE; POLYMERASE CHAIN REACTION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; RNA SEQUENCE; TUMOR INVASION; UNFOLDED PROTEIN RESPONSE; WESTERN BLOTTING; XTT ASSAY;

EID: 85011802322     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2016.11.008     Document Type: Article

References (45)

1. Holohan C, Van Schaeybroeck S, Longley DB, and Johnston PG (2013). Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13(10), 714–726. http://dx.doi.org/10.1038/nrc3599.
2. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, and Troeger J, et al (2015). Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527(7579), 472–476. http://dx.doi.org/10.1038/nature15748.
3. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, and Kalluri R (2015). Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527(7579), 525–530. http://dx.doi.org/10.1038/nature16064.
4. Zavadil J and Böttinger EP (2005). TGF-b and epithelial-to-mesenchymal transitions. Oncogene 24(37), 5764–5774. http://dx.doi.org/10.1038/sj.onc.1208927.
5. Matsuoka J, Yashiro M, Doi Y, Fuyuhiro Y, Kato Y, Shinto O, Noda S, Kashiwagi S, Aomatsu N, and Hirakawa T, et al (2013). Hypoxia stimulates the EMT of gastric cancer cells through autocrine TGFβ signaling. PLoS One 8(5), e62310. http://dx.doi.org/10.1371/journal.pone.0062310.
6. Katsuno Y, Lamouille S, and Derynck R (2013). TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 25(1), 76–84. http://dx.doi.org/10.1097/CCO.0b013e32835b6371.
7. Zhang L, Huang G, Li X, Zhang Y, Jiang Y, Shen J, Liu J, Wang Q, Zhu J, and Feng X, et al (2013). Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor -1α in hepatocellular carcinoma. BMC Cancer 13, 108. http://dx.doi.org/10.1186/1471-2407-13-108.
8. Du J, Sun B, Zhao X, Gu Q, Dong X, Mo J, Sun T, Wang J, Sun R, and Liu Y (2014). Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma. Gynecol Oncol 133(3), 575–583. http://dx.doi.org/10.1016/j.ygyno.2014.02.034.
9. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, and Ellis LM (2006). Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12(14 Pt 1), 4147–4153. http://dx.doi.org/10.1158/1078-0432.CCR-06-0038.
10. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, and Sarkar FH (2009). Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69(6), 2400–2407. http://dx.doi.org/10.1158/0008-5472.CAN-08-4312.
11. Puhr M, Hoefer J, Schäfer G, Erb HH, Oh SJ, Klocker H, Heidegger I, Neuwirt H, and Culig Z (2012). Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol 181(6), 2188–2201. http://dx.doi.org/10.1016/j.ajpath.2012.08.011.
12. van Malenstein H, Dekervel J, Verslype C, Van Cutsem E, Windmolders P, Nevens F, and van Pelt J (2013). Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett 329(1), 74–83. http://dx.doi.org/10.1016/j.canlet.2012.10.021.
13. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, and Shien K, et al (2012). Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 109(31), E2127-2133. http://dx.doi.org/10.1073/pnas.1203530109.
14. Grygielewicz P, Dymek B, Bujak A, Gunerka P, Stanczak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K, and Zdzalik D (2016). Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells. Gastric Cancer 19(1), 53–62. http://dx.doi.org/10.1007/s10120-014-0444-1.
15. Ma Y and Hendershot LM (2004). The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 4(12), 966–977. http://dx.doi.org/10.1038/nrc1505.
16. Shen X, Xue Y, Si Y, Wang Q, Wang Z, Yuan J, and Zhang X (2015). The unfolded protein response potentiates epithelial-to-mesenchymal transition (EMT) of gastric cancer cells under severe hypoxic conditions. Med Oncol 32(1), 447. http://dx.doi.org/10.1007/s12032-014-0447-0.
17. Walter P and Ron D (2011). The unfolded protein response: from stress pathway to homeostatic regulation. Science 334(6059), 1081–1086. http://dx.doi.org/10.1126/science.1209038.
18. Rzymski T, Milani M, Singleton DC, and Harris AL (2009). Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 8(23), 3838–3847. http://dx.doi.org/10.4161/cc.8.23.10086.
19. Feng YX, Sokol ES, Del Vecchio CA, Sanduja S, Claessen JH, Proia TA, Jin DX, Reinhardt F, Ploegh HL, and Wang Q, et al (2014). Epithelial-to-mesenchymal transition activates PERK-eIF2α and sensitizes cells to endoplasmic reticulum stress. Cancer Discov 4(6), 702–715. http://dx.doi.org/10.1158/2159-8290.CD-13-0945.
20. Wainwright M (2001). Acridine-a neglected antibacterial chromophore. J Antimicrob Chemother 47(1), 1–13. http://dx.doi.org/10.1093/jac/47.1.1.
21. Hassan S, Laryea D, Mahteme H, Felth J, Fryknäs M, Fayad W, Linder S, Rickardson L, Gullbo J, and Graf W, et al (2011). Novel activity of acriflavine against colorectal cancer tumor cells. Cancer Sci 102(12), 2206–2213. http://dx.doi.org/10.1111/j.1349-7006.2011.02097.x.
22. Lee K, Zhang H, Qian DZ, Rey S, Liu JO, and Semenza GL (2009). Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A 106(42), 17910–17915. http://dx.doi.org/10.1073/pnas. 0909353106.
23. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, and Wu KJ (2008). Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10(3), 295–305. http://dx.doi.org/10.1038/ncb1691.
24. Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, Xia XF, Sun X, Li GG, Hu QD, and Fu QH, et al (2016). Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis. Cancer Res 76(4), 818–830. http://dx.doi.org/10.1158/0008-5472.CAN-15-0977.
25. Samulitis BK, Pond KW, Pond E, Cress AE, Patel H, Wisner L, Patel C, Dorr RT, and Landowski TH (2015). Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 16(1), 43–51. http://dx.doi.org/10.4161/15384047.2014.986967.
26. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, and Gentry J, et al (2004). Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5(10), R80. http://dx.doi.org/10.1186/gb-2004-5-10-r80.
27. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29(1), 15–21. http://dx.doi.org/10.1093/bioinformatics/bts635.
28. Liao Y, Smyth GK, and Shi W (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30(7), 923–930. http://dx.doi.org/10.1093/bioinformatics/btt656.
29. Robinson MD and Smyth GK (2007). Moderated statistical tests for assessing differences in tag abundance. Bioinformatics 23(21), 2881–2887. http://dx.doi.org/10.1093/bioinformatics/btm453.
30. Benjamini Y and Hochberg Y (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57, 289–300 [http://www.jstor.org/stable/2346101?origin=JSTOR-pdf&seq=1#page_scan_tab_contents].
31. Janky R, Verfaillie A, Imrichová H, Van de Sande B, Standaert L, Christiaens V, Hulselmans G, Herten K, Naval Sanchez M, and Potier D, et al (2014). iRegulon: from a gene list to a gene regulatory network using large motif and track col l ecti ons. PLoS Comput Bi ol 10(7), e1003731. http://dx.doi.org/10.1371/journal.pcbi.1003731.
32. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, and Lander ES, et al (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102(43), 15545–15550. http://dx.doi.org/10.1016/j.ygyno.2014.02.034.
33. Igarashi T, Izumi H, Uchiumi T, Nishio K, Arao T, Tanabe M, Uramoto H, Sugio K, Yasumoto K, and Sasaguri Y, et al (2007). Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 26(33), 4749–4760. http://dx.doi.org/10.1038/sj.onc.1210289.
34. van den Beucken T, Koritzinsky M, Niessen H, Dubois L, Savelkouls K, Mujcic H, Jutten B, Kopacek J, Pastorekova S, and van der Kogel AJ, et al (2009). Hypoxia-induced expression of carbonic anhydrase 9 is dependent on the unfolded protein response. J Biol Chem 284(36), 24204–24212. http://dx.doi.org/10.1074/jbc.M109.006510.
35. van den Beucken T, Ramaekers CH, Rouschop K, Koritzinsky M, and Wouters BG (2009). Deficient carbonic anhydrase 9 expression in UPR-impaired cells is associated with reduced survival in an acidic microenvironment. Radiother Oncol 92(3), 437–442. http://dx.doi.org/10.1016/j.radonc.2009.06.018.
36. Seton-Rogers S (2016). Epithelial-mesenchymal transition: Untangling EMT's functions. Nat Rev Cancer 16(1), 1. http://dx.doi.org/10.1038/nrc.2015.6.
37. Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, and Michor F, et al (2013). Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res 23(9), 1434–1445. http://dx.doi.org/10.1101/gr.152322.112.
38. Vandewynckel YP, Laukens D, Geerts A, Bogaerts E, Paridaens A, Verhelst X, Janssens S, Heindryckx F, and Van Vlierberghe H (2013). The paradox of the unfolded protein response in cancer. Anticancer Res 33(11), 4683–4694 [http://ar.iiarjournals.org/content/33/11/4683.long].
39. Rzymski T and Harris AL (2007). The unfolded protein response and integrated stress response to anoxia. Clin Cancer Res 13(9), 2537–2540. http://dx.doi.org/10.1158/1078-0432.CCR-06-2126.
40. Singleton DC and Harris AL (2012). Targeting the ATF4 pathway in cancer therapy. Expert Opin Ther Targets 16(12), 1189–1202. http://dx.doi.org/10.1517/ 14728222.2012.728207.
41. Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, Kyle A, Auf dem Keller U, Leung S, and Huntsman D, et al (2011). Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 71(9), 3364–3376. http://dx.doi.org/10.1158/0008-5472.CAN-10-4261.
42. Fels DR and Koumenis C (2006). The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol Ther 5(7), 723–728. http://dx.doi.org/10.4161/cbt.5.7.2967.
43. Wong CC, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, Hubbi ME, and Semenza GL (2012). Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med 90(7), 803–815. http://dx.doi.org/10.1007/s00109-011-0855-y.
44. Assinder E (1936). Acriflavine as a urinary antiseptic. Lancet 227(5867), 304–305.
45. Semenza GL (2012). Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33(4), 207–214. http://dx.doi.org/10.1016/j.tips.2012.01.005.